Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Catherine Ellis(GlaxoSmithKline (United States)), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giancarlo Bisagni, Guido Ficarra(University of Modena and Reggio Emilia), Silvio Bicciato(University of Modena and Reggio Emilia), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Rocco J. Crescenzo(Pfizer (United States)), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Stefania Bettelli(University of Modena and Reggio Emilia), Enrico Tagliafico(University of Modena and Reggio Emilia), Antonino Maiorana(University of Modena and Reggio Emilia), Maria Vittoria Dieci(Istituto Oncologico Veneto), Daniele Generali(University of Trieste)
Cited by 114
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
|Cell|2011|1.4k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells
|Nature Cell Biology|2007|979